BIB

Fund Description
ProShares Ultra Nasdaq Biotechnology seeks daily investment results before fees and expenses that correspond to twice (200%) the daily performance of the NASDAQ Biotechnology Index.
Fund Profile
Fund Name ProShares Ultra Nasdaq Biotechnology
Fund Exchange Ticker BIB
Fund Sponsor ProShares
Fund ISIN US74347R2141
Net Expense Ratio 0.95 %
Fund Inception Date 7 April 2010
Fund Legal Structure ETF (Open end fund)
Exchange NASDAQ
Listing Country Code US
Fund Investment Objective
ETF Type Specific Leveraged / Inverse
Asset Class Equities (Stocks)
Index Linked Passive
Index Name Nasdaq Biotech Index
Index Provider Nasdaq
Currency Hedged No
Inverse / Leveraged Leveraged (2x)
Developed / Emerging Developed Market Funds
Market Capitalization Range Broad Market / Multi-Cap
Growth Value Core / Blend
Continent North America
Key Statistics
Return As of Date 23 October 2020
Asset Under Management 197.95 Million (USD)
1 Month Total Return 8.43 %
Year To Date Return 14.56 %
1 Year Total Return 48.21 %
3 Year Annualized Total Return 6.18 %
NAV 70.6952
Share Outstanding 2,800,000
Top 10 Holdings (23 October 2020)
Constituent Name Constituent Ticker Constituent Type Weighting
ESPERION THERAPEUTICS INC ESPR EQUI
Net Other Assets / Cash CASH
CONTRA RESTORBIO INC EQUI
EYEPOINT PHARMACEUTICALS INC EYPT EQUI
XERIS PHARMACEUTICALS INC XERS EQUI
ACHILLION PHARMACEUTICALS INC COMMON STOCK USD ACHN EQUI
CORBUS PHARMACEUTICALS HOLDI CRBP EQUI
GRITSTONE ONCOLOGY INC GRTS EQUI
EVOLUS INC EOLS EQUI
GLYCOMIMETICS INC GLYC EQUI